Online Inquiry
PTEN (-/-) Cell Line
SPL-02874
| Size | Price |
| 1 Unit | Online Inquiry |
| Description |
|---|
| PTEN (-/-) |
| Target Information | |
|---|---|
| Target Name | PTEN |
| Gene Abbr. | PTEN |
| Gene ID | 5728 |
| Full Name | phosphatase and tensin homolog |
| Alias | 10q23del, BZS, CWS1, DEC, GLM2 |
| Species | Human |
| Genomic Locus | 10q23.3 |
| Introduction | This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]. |
| Product Details | |
|---|---|
| Cell Line Model | MCF10A |
| Genotype | PTEN (-/-) |
| Description | PTEN (-/-) |
| Parental ATCC ID | CRL-10317 |
| STR Profile | Amelogenin: X; CSF1PO: 10,12; D13S317: 8,9; D16S539: 11,12; D5S818: 10,13; D7S820: 10,11; THO1: 8,9.3; TPOX: 9,11; vWA: 15,17; ATCC |
| Disease | Epithelial |
| Tissue | Breast |
| Gender | Female |
| Key Endogenous Mutations | none listed |
| CVT Selection Condition | No antibiotic resistance |
| Cell Number | 1x10^6 |
| Handling Specifications | |
|---|---|
| Revival | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Culture Medium | DMEM/F-12 including 2.5 mM L-glutamine and 15 mM HEPES, supplemented with 5% horse serum, 10 µg/mL insulin, 20 ng/mL hEGF, 0.5 µg/mL hydrocortisone, 0.1 µg/mL cholera toxin. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Cells should be passaged every 3-5 days. Split at 80-90% confluency, approximately 1:6-1:10. |
| Freeze Medium | Complete growth media 45% + USDA approved FBS 50% + DMSO 5% |
| Biosafety Level | BSL-1 |
| Disclaimer | This product is classified under IATA regulations as a GMMO (genetically modified micro-organism) and will ship as UN3245. If applicable, ensure facility meets all requirements per local and country regulations. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.